The second incretin, GIP, whose receptors reside in adipose tissue, increases insulin secretion and suppresses glucagon release
Patients often report improvements in conditions associated with excess body fat, such as lower cholesterol, blood pressure, and blood sugar levels
Frequently Asked Questions What weight loss was achieved with retatrutide in the phase 2 NEJM trial at 48 weeks
Tirzepatide can cause fatigue and dizziness
Agonists Exendin-4 (subsequently renamed exenatide, the first FDA approved incretin mimetic), Liraglutide (a longacting DPP-4-resistant GLP-1 receptor agonist), CJC-1131 (a GLP-1 analog engineered for covalent coupling to albumin), Albiglutide (originally referred to as albugon, a recombinant human albumin-GLP-1 protein), ZP10 (an exendin-4 derivative), BIM51077 (subsequently renamed taspoglutide), LY315902 (a DPP-4-resistant GLP-1 analog), LY2428757 (a pegylated GLP-1), LY2199265 (Dulaglutide, an Fc immunoglobulin fusion protein), Semaglutide (a synthetic peptide similar to GLP-1), Lixisenatide (a synthetic peptide similar to exandin-4), and Tirzepatide (LY3298176, a dual agonist of GIP and GLP-1 receptors)
Lets break them down in simple terms How These Medications Actually Work (Plain English Version) All three medications talk to your hormones the chemical messengers that decide: How hungry you feel How full you get How fast (or slow) you burn calories They just talk to different combinations of hormones
